Key Points
- Junlin Ho sold 9,580 shares of Scholar Rock on Feb. 17 at an average price of $46.53 for proceeds of $445,757, reducing his stake by 3.81% to 241,545 shares (valued at about $11.24M).
- Large institutional investors materially increased holdings—Siren, Wellington, Vanguard, State Street and Orbis Allan Gray all added shares—leaving 91.08% of SRRK owned by institutions and hedge funds.
- Analyst sentiment is positive with a consensus "Buy" rating and an average target of $51.14; the stock recently traded near $47.92, has a $4.89B market cap, and shows strong liquidity (quick/current ratio 6.30).
Scholar Rock Holding Corporation (NASDAQ:SRRK - Get Free Report) insider Jing Marantz sold 4,157 shares of the stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $46.53, for a total transaction of $193,425.21. Following the transaction, the insider directly owned 126,012 shares in the company, valued at approximately $5,863,338.36. This represents a 3.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Scholar Rock Trading Up 0.4%
Shares of SRRK traded up $0.19 during trading hours on Friday, hitting $47.89. The company had a trading volume of 808,795 shares, compared to its average volume of 998,473. The firm has a market cap of $4.89 billion, a P/E ratio of -15.30 and a beta of 0.67. Scholar Rock Holding Corporation has a 52-week low of $22.71 and a 52-week high of $49.82. The stock's 50 day moving average price is $45.14 and its 200 day moving average price is $38.30. The company has a quick ratio of 6.30, a current ratio of 6.30 and a debt-to-equity ratio of 0.41.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of the company. Moody Aldrich Partners LLC grew its position in shares of Scholar Rock by 53.5% during the 3rd quarter. Moody Aldrich Partners LLC now owns 101,742 shares of the company's stock valued at $3,789,000 after acquiring an additional 35,481 shares during the period. Norges Bank bought a new stake in Scholar Rock during the second quarter valued at about $41,628,000. Voya Investment Management LLC grew its holdings in Scholar Rock by 18.1% during the third quarter. Voya Investment Management LLC now owns 443,155 shares of the company's stock valued at $16,503,000 after purchasing an additional 67,839 shares during the period. Ensign Peak Advisors Inc raised its stake in shares of Scholar Rock by 78.8% in the second quarter. Ensign Peak Advisors Inc now owns 600,639 shares of the company's stock worth $21,275,000 after buying an additional 264,693 shares during the period. Finally, Nan Fung Trinity HK Ltd. purchased a new position in shares of Scholar Rock during the 3rd quarter valued at about $1,402,000. 91.08% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several analysts recently issued reports on the company. Barclays raised their target price on Scholar Rock from $45.00 to $52.00 and gave the stock an "overweight" rating in a research note on Wednesday, December 17th. Citigroup started coverage on Scholar Rock in a report on Friday, January 9th. They set a "buy" rating and a $55.00 price target for the company. Wolfe Research initiated coverage on shares of Scholar Rock in a research note on Tuesday, November 18th. They issued an "outperform" rating and a $42.00 price target on the stock. JPMorgan Chase & Co. raised their price objective on shares of Scholar Rock from $46.00 to $47.00 and gave the company an "overweight" rating in a research note on Tuesday, November 18th. Finally, BMO Capital Markets reiterated an "outperform" rating and issued a $50.00 target price on shares of Scholar Rock in a research note on Friday, November 14th. Four investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $51.14.
Read Our Latest Stock Analysis on Scholar Rock
About Scholar Rock
(
Get Free Report)
Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company's research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock's approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.
The company's lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
